Home / Intelligence / News / Trinity and Pfizer Present Panel Discussion on Tissue-Agnostic Cancer Drug Development
Waltham, MA—Global life sciences consulting firm Trinity today announced it will present the panel discussion, “Tissue-Agnostic Cancer Drug Development: An Emerging Paradigm Shift?” along with Pfizer and the Healthcare Businesswomen’s Association (HBA). The event, featuring perspectives from clinical, commercial, regulatory and market access experts, will take place at Pfizer’s headquarters in New York City on October 23, 2018 from 5:30-8 pm.
Cancer treatment has made significant strides toward the promise of personalized medicine in recent years. With Keytruda’s tissue-agnostic MSI-H/dMMR approval last year, basket trials are now a viable registrational strategy to pursue such tissue-agnostic, biomarker-based indications. The panel will focus on what this means for oncology treatment and for industry, including whether it will lead to a shift in the oncology treatment paradigm.
The discussion will be moderated by Geeta Devgan, PhD, Medical Director of US Medical Affairs, Pfizer Oncology. Panelists include:
- David Hyman, MD, Chief, Early Drug Development, Memorial Sloan Kettering Cancer Center
- Chris Boshoff, MD, PhD, Head & SVP of Immuno-Oncology, Early Development & Translational Oncology, Pfizer
- Jillian Scaife, MPH, MBA, Principal, Trinity
- Leigh Marcus, MD, Medical Officer, Office of Hematology & Oncology Products, CDER, FDA
- Nitin Patel, Sr. Principal, Market Access, IQVIA
“While the emergence of truly registrational basket trials have been limited to-date, the growing pool of mid-phase and/or exploratory tissue-agnostic trials suggests that, in the near term, interest in tissue-agnostic basket trial development is likely to grow,” said Jillian Scaife. “It is critical to consider the potential impact multiple oncology products approved with tissue-agnostic indications could have for oncology treatment and for industry.”
Trinity is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create tailored, evidence-based solutions that drive business strategy and impact bottom lines. Trinity works with more than 100 clients annually, including 18 of the top 25 global biopharmaceutical companies and dozens of leading medical device and diagnostic companies. Trinity has over 150 professionals on staff that focus solely on the life sciences industry. Trinity is partnered with Parthenon Capital Partners, a leading, growth-oriented private equity firm. To learn more about Trinity, click here.
Sign up for the latest intelligence